Clinical Trial: Fluorine F 18 Clofarabine PET/CT in Imaging Patients With Autoimmune or Inflammatory Diseases
Study Status: Recruiting
Recruit Status: Recruiting
Study Type: Interventional
Official Title: The Biodistribution of 18F-Clofarabine in Patients With Autoimmune and Inflammatory Diseases
Brief Summary: This pilot trial studies how well fluorine F 18 clofarabine positron emission tomography (PET)/computed tomography (CT) works in imaging patients with autoimmune or inflammatory diseases. Fluorine F 18 clofarabine is an imaging agent or tracer which may be taken up by inflammatory tissue in the body. Diagnostic imaging, such as PET/CT scans, can be used to measure the amount of injected tracer that is taken up by inflammatory tissue. PET/CT scan may help to determine how fluorine F 18 clofarabine is distributed throughout the body.
Detailed Summary:
PRIMARY OBJECTIVES:
I. Determine how fluorine F 18 clofarabine (18F‐clofarabine) is distributed in the body, in patients with autoimmune and inflammatory diseases.
II. Determine whether 18F‐clofarabine can be used to image patients with autoimmune and inflammatory diseases.
OUTLINE:
Patients receive fluorine F 18 clofarabine intravenously (IV) and undergo a single PET/CT scan for up to 120 minutes.
Sponsor: Jonsson Comprehensive Cancer Center
Current Primary Outcome: Standardized Uptake Value [ Time Frame: Baseline up to 240 minutes after injection ]
Original Primary Outcome: Same as current
Current Secondary Outcome:
Original Secondary Outcome:
Information By: Jonsson Comprehensive Cancer Center
Dates:
Date Received: September 8, 2016
Date Started: January 2016
Date Completion: August 2022
Last Updated: October 4, 2016
Last Verified: September 2016